atezolizumab + bevacizumab + yttrium-90

This is a **combination therapy** consisting of **atezolizumab** (a PD-L1 immune checkpoint inhibitor), **bevacizumab** (a monoclonal antibody targeting VEGF), and **yttrium-90** (a radioactive isotope administered as microspheres for transarterial radioembolization, also known as Y90 or TARE). This regimen is being investigated for the treatment of **advanced or unresectable hepatocellular carcinoma (HCC)**. Atezolizumab activates the immune system by preventing PD-L1-mediated inhibition of T cells, bevacizumab inhibits angiogenesis by blocking VEGF, and yttrium-90 delivers targeted internal radiation directly to liver tumors, maximizing local control while sparing healthy liver tissue. The combination aims to harness immunotherapy and targeted anti-angiogenic therapy with local radiotherapy to provide synergistic effects, improving tumor response and survival in patients with HCC[1][4][7].

Brand names

TecentriqAvastin

Other names

SIRT-Y90 plus atezolizumab and bevacizumabSIRT-Y-90 plus atezolizumab and bevacizumabSIRT-Y 90 plus atezolizumab and bevacizumabY-90 radioembolization plus atezolizumab and bevacizumabY90 radioembolization plus atezolizumab and bevacizumabY 90 radioembolization plus atezolizumab and bevacizumab